Cargando…

Luteolin Alleviates Liver Fibrosis in Rat Hepatic Stellate Cell HSC-T6: A Proteomic Analysis

BACKGROUND: Traditional Chinese medicine (TCM) with single or compound materials is an effective cure for liver fibrosis. Hepatic stellate cells (HSCs) play a key role in liver fibrosis pathology and have become a novel drug target for this condition. METHODS: CCK-8 assay was used to determine the c...

Descripción completa

Detalles Bibliográficos
Autores principales: Batudeligen, Han, Zhiqiang, Chen, Hongmei, Narisu, Xu, Yanhua, Anda, Han, Gegentaoli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285022/
https://www.ncbi.nlm.nih.gov/pubmed/37360572
http://dx.doi.org/10.2147/DDDT.S402864
_version_ 1785061520643719168
author Batudeligen
Han, Zhiqiang
Chen, Hongmei
Narisu
Xu, Yanhua
Anda
Han, Gegentaoli
author_facet Batudeligen
Han, Zhiqiang
Chen, Hongmei
Narisu
Xu, Yanhua
Anda
Han, Gegentaoli
author_sort Batudeligen
collection PubMed
description BACKGROUND: Traditional Chinese medicine (TCM) with single or compound materials is an effective cure for liver fibrosis. Hepatic stellate cells (HSCs) play a key role in liver fibrosis pathology and have become a novel drug target for this condition. METHODS: CCK-8 assay was used to determine the cytotoxicity of four components, SYPA, HSYPA, Apigenin, and Luteolin, from Deduhonghua-7 powder on HSC-T6 cells. Transforming Growth Factor β 1 (TGFβ1)-induced fibrotic cell model and CCI(4)-induced fibrotic rat model were constructed, the expression of fibrosis-related genes, the pathological changes and serum biochemical markers were evaluated. Proteomic analysis was performed to determine the mechanism by which luteolin attenuated liver fibrosis, which were further confirmed by Western blot. RESULTS: Luteolin attenuates liver fibrosis in HSC-T6 cells and luteolin decreases the liver fibrosis index level in vivo. A total of 5000 differentially expressed proteins (DEPs) were obtained using proteomic analysis. KEGG analysis found that DEPs were concentrated in various metabolic pathways, including DNA replication and repair and lysosomal signaling. GO analysis showed that molecular functions included the activity and binding of various enzymes, related cellular components included the extracellular space, lysosomal lumen, mitochondrial matrix, and nucleus, and biological processes included collagen organization and biosynthesis and the positive regulation of cell migration. Western blot results showed that CCR1, CD59, and NAGA were downregulated in TGFβ1 treatment, while upregulated both in Lut2 and Lut10 treatment. Meanwhile, eight proteins, ITIH3, MKI67, KIF23, DNMT1, P4HA3, CCDC80, APOB, FBLN2, that were upregulated in TGFβ1 treatment, while downregulated both in Lut2 and Lut10 treatment. CONCLUSION: Luteolin was shown to have a strong protective effect on liver fibrosis. CCR1, CD59, and NAGA may promote liver fibrosis while ITIH3, MKI67, KIF23, DNMT1, P4HA3, CCDC80, APOB, and FBLN2 may facilitate protection against fibrosis.
format Online
Article
Text
id pubmed-10285022
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-102850222023-06-23 Luteolin Alleviates Liver Fibrosis in Rat Hepatic Stellate Cell HSC-T6: A Proteomic Analysis Batudeligen Han, Zhiqiang Chen, Hongmei Narisu Xu, Yanhua Anda Han, Gegentaoli Drug Des Devel Ther Original Research BACKGROUND: Traditional Chinese medicine (TCM) with single or compound materials is an effective cure for liver fibrosis. Hepatic stellate cells (HSCs) play a key role in liver fibrosis pathology and have become a novel drug target for this condition. METHODS: CCK-8 assay was used to determine the cytotoxicity of four components, SYPA, HSYPA, Apigenin, and Luteolin, from Deduhonghua-7 powder on HSC-T6 cells. Transforming Growth Factor β 1 (TGFβ1)-induced fibrotic cell model and CCI(4)-induced fibrotic rat model were constructed, the expression of fibrosis-related genes, the pathological changes and serum biochemical markers were evaluated. Proteomic analysis was performed to determine the mechanism by which luteolin attenuated liver fibrosis, which were further confirmed by Western blot. RESULTS: Luteolin attenuates liver fibrosis in HSC-T6 cells and luteolin decreases the liver fibrosis index level in vivo. A total of 5000 differentially expressed proteins (DEPs) were obtained using proteomic analysis. KEGG analysis found that DEPs were concentrated in various metabolic pathways, including DNA replication and repair and lysosomal signaling. GO analysis showed that molecular functions included the activity and binding of various enzymes, related cellular components included the extracellular space, lysosomal lumen, mitochondrial matrix, and nucleus, and biological processes included collagen organization and biosynthesis and the positive regulation of cell migration. Western blot results showed that CCR1, CD59, and NAGA were downregulated in TGFβ1 treatment, while upregulated both in Lut2 and Lut10 treatment. Meanwhile, eight proteins, ITIH3, MKI67, KIF23, DNMT1, P4HA3, CCDC80, APOB, FBLN2, that were upregulated in TGFβ1 treatment, while downregulated both in Lut2 and Lut10 treatment. CONCLUSION: Luteolin was shown to have a strong protective effect on liver fibrosis. CCR1, CD59, and NAGA may promote liver fibrosis while ITIH3, MKI67, KIF23, DNMT1, P4HA3, CCDC80, APOB, and FBLN2 may facilitate protection against fibrosis. Dove 2023-06-17 /pmc/articles/PMC10285022/ /pubmed/37360572 http://dx.doi.org/10.2147/DDDT.S402864 Text en © 2023 Batudeligen et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Batudeligen
Han, Zhiqiang
Chen, Hongmei
Narisu
Xu, Yanhua
Anda
Han, Gegentaoli
Luteolin Alleviates Liver Fibrosis in Rat Hepatic Stellate Cell HSC-T6: A Proteomic Analysis
title Luteolin Alleviates Liver Fibrosis in Rat Hepatic Stellate Cell HSC-T6: A Proteomic Analysis
title_full Luteolin Alleviates Liver Fibrosis in Rat Hepatic Stellate Cell HSC-T6: A Proteomic Analysis
title_fullStr Luteolin Alleviates Liver Fibrosis in Rat Hepatic Stellate Cell HSC-T6: A Proteomic Analysis
title_full_unstemmed Luteolin Alleviates Liver Fibrosis in Rat Hepatic Stellate Cell HSC-T6: A Proteomic Analysis
title_short Luteolin Alleviates Liver Fibrosis in Rat Hepatic Stellate Cell HSC-T6: A Proteomic Analysis
title_sort luteolin alleviates liver fibrosis in rat hepatic stellate cell hsc-t6: a proteomic analysis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285022/
https://www.ncbi.nlm.nih.gov/pubmed/37360572
http://dx.doi.org/10.2147/DDDT.S402864
work_keys_str_mv AT batudeligen luteolinalleviatesliverfibrosisinrathepaticstellatecellhsct6aproteomicanalysis
AT hanzhiqiang luteolinalleviatesliverfibrosisinrathepaticstellatecellhsct6aproteomicanalysis
AT chenhongmei luteolinalleviatesliverfibrosisinrathepaticstellatecellhsct6aproteomicanalysis
AT narisu luteolinalleviatesliverfibrosisinrathepaticstellatecellhsct6aproteomicanalysis
AT xuyanhua luteolinalleviatesliverfibrosisinrathepaticstellatecellhsct6aproteomicanalysis
AT anda luteolinalleviatesliverfibrosisinrathepaticstellatecellhsct6aproteomicanalysis
AT hangegentaoli luteolinalleviatesliverfibrosisinrathepaticstellatecellhsct6aproteomicanalysis